Leishmaniasis, lupus nephritis and immunosuppressive therapy

QJM. 2016 Jan;109(1):51-2. doi: 10.1093/qjmed/hcv069. Epub 2015 Mar 18.

Authors

J A Vargas-Hitos¹, R Roa-Chamorro², J M Sabio², R Javier-Martínez³, A Martín-Castro⁴, J Jiménez-Alonso²

Affiliations

¹ From the Systemic Autoimmune Diseases Unit, Internal Medicine Department, joseantoniovh@hotmail.com.
² From the Systemic Autoimmune Diseases Unit, Internal Medicine Department.
³ Infectious Diseases Department and.
⁴ Histopathology Department, Virgen de las Nieves, University Hospital, Granada, Spain.

PMID: 25788407
DOI: 10.1093/qjmed/hcv069

No abstract available

Publication types

Case Reports

MeSH terms

Amphotericin B / therapeutic use
Antiprotozoal Agents / therapeutic use
Female
Humans
Immunosuppressive Agents / adverse effects*
Leishmania infantum
Leishmaniasis / drug therapy
Leishmaniasis / pathology*
Lupus Nephritis / complications*
Lupus Nephritis / drug therapy
Middle Aged
Mycophenolic Acid / adverse effects
Mycophenolic Acid / analogs & derivatives*

Substances

Antiprotozoal Agents
Immunosuppressive Agents
Amphotericin B
Mycophenolic Acid